Vita-Herb Nutriceuticals, Inc. – Trademark Portfolio

Entity Type: 03

Vita-Herb Nutriceuticals, Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 40 (Treatment & Processing) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include NPIB and SCAP / MCAP. The owner is based in Placentia, CA.

172 E. La Jolla St

Placentia, CA 928701944

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Vita-Herb Nutriceuticals, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

40
Treatment & Processing (6 filings)

Treatment of materials

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Vita-Herb Nutriceuticals, Inc. have?

Vita-Herb Nutriceuticals, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned, 4 cancelled.

What trademark classes does Vita-Herb Nutriceuticals, Inc. file in?

Vita-Herb Nutriceuticals, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 40 (Treatment & Processing), Class 5 (Pharmaceuticals). Class 40 covers treatment of materials.

What are Vita-Herb Nutriceuticals, Inc.'s most well-known trademarks?

Vita-Herb Nutriceuticals, Inc.'s registered trademark portfolio includes well-known marks such as NPIB and SCAP / MCAP. These are among 2 currently registered trademarks in the portfolio.

What is Vita-Herb Nutriceuticals, Inc.'s trademark registration success rate?

Vita-Herb Nutriceuticals, Inc. has a 20% trademark registration rate, with 2 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.